- History
- Examination
- Investigations
- Drug Guide
- Full List
- Anthropometry
- Blood Gas Analyser
- Cardiovascular
- Respiratory
- Gastrointestinal
- Neurological
- Biochemistry
- Haematology
- Critical Care
- Trauma
- Obstetrics
Gastro Drugs
Gastro Drugs
Antiemetics
Gastric Secretion Modulators
Laxatives
Inflammatory Bowel Disease Medications
Systemic Corticosteroids
Prednisolone, hydrocortisone
Systemic anti-inflammatory action
Aminosalicylates
Mesalazine, sulfasalazine
↑ Adenosine release →↓ inflammation
Thiopurines
Azathioprine (AZA), 6-Mercaptopurine (6-MP)
Inhibit purine synthesis → ↓ DNA synthesis
Methotrexate
Inhibition of IL-1 / other cytokines
TNF Inhibitors
Infliximab, adalimumab
Inhibit tumour necrosis factor α →↓ inflammation
Anti-IL-12/23 Agents
Ustekinumab
Monoclonal Ab vs p40 subunit of IL-12 and IL-23
Serotonin Receptor Blockers
- Oral / Subling / IM / IVOndansetronZofran
Overview
Mechanism of Action
Selectively antagonize serotonin (5-HT3) receptors within the central nervous system.
Clinical Use
Indications
- Nausea / vomiting secondary to chemotherapy or radiotherapy
- Postoperative nausea / vomiting
Adverse Effects
- Headache
- Diarrhoea
- Fatigue
Last updated on January 1st, 2017
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Read More...
The information in this section has been adapted in part from the Australian Therapeutic Goods Association website's repository of product information documents, which are available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI.
Aarbakke J, Janka-Schaub G, Elion GB. Thiopurine biology and pharmacology. Trends in pharmacological sciences. 1997 Jan 1;18(1):3-7.Giraldo J, Martín M, Campillo M, Pardo L. Theoretical studies on the histamine H2 receptor: molecular mechanism of action of antagonists. Molecular Pharmacology. 1992 Aug; 42: 2373-381.Hanauer SB. Aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics. 2004;20:60-65.Hay AM. Proceedings: The mechanism of action of metoclopramide. Gut. 1975; 16(5): 403.Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of Action of 6-Thioguanine, 6-Mercaptopurine, and 8-Azaguanine. Cancer Res October 1975 35; 2872.Roila F, Tonato M, Basurto C, Bracarda S, Sassi M et al. Ondansetron. European Journal of Cancer. 1993; 29(1 Suppl): S16-S21.Shin JM, Sachs G. Pharmacology of proton pump inhibitors.Current Gastroenterology Reports. 2008;10:528-534.Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002; 66: 27380.Wallmark B. Mechanism of action of omeprazole. Scandinavian journal of gastroenterology. 1986; 118(Suppl): 11.Watcha MF, White PF. 9 Antiemetics. Bailliere's Clinical Anaesthesiology. 1995 Mar; 9(1): 119-136.